Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials

Guru Sonpavde; Youjin Je; Fabio Schutz; Matthew D. Galsky; Ravikumar Paluri; Jonathan E. Rosenberg; Joaquim Bellmunt; Toni K. Choueiri

doi:10.1016/j.critrevonc.2012.12.006

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials

Guru Sonpavde, Youjin Je, Fabio Schutz, Matthew D. Galsky, Ravikumar Paluri, Jonathan E. Rosenberg, Joaquim Bellmunt, Toni K. Choueiri

Research output: Contribution to journal › Review article › peer-review

60 Citations (Scopus)

Abstract

A trial-level meta-analysis was conducted to determine the relative risk (RR) of venous thromboembolic events (VTEs) associated with approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized phase 2 and 3 trials comparing arms with and without a Food and Drug Administration-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, vandetanib, and axitinib). Statistical analyses calculated the RR and 95% confidence intervals (CI), using random-effects or fixed-effects models based on heterogeneity. A total of 7441 patients from 9 phase III trials and 8 phase II trials were selected. The RR of all grade and high-grade VTEs for the TKI vs. no TKI arms was 1.10 (95% CI 0.73-1.66, p=0.64) and 0.85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found.

Original language	English
Pages (from-to)	80-89
Number of pages	10
Journal	Critical Reviews in Oncology/Hematology
Volume	87
Issue number	1
DOIs	https://doi.org/10.1016/j.critrevonc.2012.12.006
Publication status	Published - Jul 2013

Bibliographical note

Funding Information:
This study was funded by the philanthropic Trust Family Research Fund for Kidney Cancer. The funding source did not have any role in this study. The authors had access to all raw data and had the final responsibility for the decision to submit the manuscript for publication.

Keywords

Approved
Meta-analysis
Tyrosine kinase inhibitors
Vascular endothelial growth factor receptor
Venous thromboembolic events

Access to Document

10.1016/j.critrevonc.2012.12.006

Cite this

Sonpavde, G., Je, Y., Schutz, F., Galsky, M. D., Paluri, R., Rosenberg, J. E., Bellmunt, J., & Choueiri, T. K. (2013). Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 87(1), 80-89. https://doi.org/10.1016/j.critrevonc.2012.12.006

@article{c2ee6eb01cfe4ab6bffc41ff74cf0f10,

title = "Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials",

abstract = "A trial-level meta-analysis was conducted to determine the relative risk (RR) of venous thromboembolic events (VTEs) associated with approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized phase 2 and 3 trials comparing arms with and without a Food and Drug Administration-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, vandetanib, and axitinib). Statistical analyses calculated the RR and 95% confidence intervals (CI), using random-effects or fixed-effects models based on heterogeneity. A total of 7441 patients from 9 phase III trials and 8 phase II trials were selected. The RR of all grade and high-grade VTEs for the TKI vs. no TKI arms was 1.10 (95% CI 0.73-1.66, p=0.64) and 0.85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found.",

keywords = "Approved, Meta-analysis, Tyrosine kinase inhibitors, Vascular endothelial growth factor receptor, Venous thromboembolic events",

author = "Guru Sonpavde and Youjin Je and Fabio Schutz and Galsky, {Matthew D.} and Ravikumar Paluri and Rosenberg, {Jonathan E.} and Joaquim Bellmunt and Choueiri, {Toni K.}",

note = "Funding Information: This study was funded by the philanthropic Trust Family Research Fund for Kidney Cancer. The funding source did not have any role in this study. The authors had access to all raw data and had the final responsibility for the decision to submit the manuscript for publication. ",

year = "2013",

month = jul,

doi = "10.1016/j.critrevonc.2012.12.006",

language = "English",

volume = "87",

pages = "80--89",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

Sonpavde, G, Je, Y, Schutz, F, Galsky, MD, Paluri, R, Rosenberg, JE, Bellmunt, J & Choueiri, TK 2013, 'Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials', Critical Reviews in Oncology/Hematology, vol. 87, no. 1, pp. 80-89. https://doi.org/10.1016/j.critrevonc.2012.12.006

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. / Sonpavde, Guru; Je, Youjin; Schutz, Fabio et al.
In: Critical Reviews in Oncology/Hematology, Vol. 87, No. 1, 07.2013, p. 80-89.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors

T2 - A systematic review and meta-analysis of randomized clinical trials

AU - Sonpavde, Guru

AU - Je, Youjin

AU - Schutz, Fabio

AU - Galsky, Matthew D.

AU - Paluri, Ravikumar

AU - Rosenberg, Jonathan E.

AU - Bellmunt, Joaquim

AU - Choueiri, Toni K.

N1 - Funding Information: This study was funded by the philanthropic Trust Family Research Fund for Kidney Cancer. The funding source did not have any role in this study. The authors had access to all raw data and had the final responsibility for the decision to submit the manuscript for publication.

PY - 2013/7

Y1 - 2013/7

N2 - A trial-level meta-analysis was conducted to determine the relative risk (RR) of venous thromboembolic events (VTEs) associated with approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized phase 2 and 3 trials comparing arms with and without a Food and Drug Administration-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, vandetanib, and axitinib). Statistical analyses calculated the RR and 95% confidence intervals (CI), using random-effects or fixed-effects models based on heterogeneity. A total of 7441 patients from 9 phase III trials and 8 phase II trials were selected. The RR of all grade and high-grade VTEs for the TKI vs. no TKI arms was 1.10 (95% CI 0.73-1.66, p=0.64) and 0.85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found.

AB - A trial-level meta-analysis was conducted to determine the relative risk (RR) of venous thromboembolic events (VTEs) associated with approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized phase 2 and 3 trials comparing arms with and without a Food and Drug Administration-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, vandetanib, and axitinib). Statistical analyses calculated the RR and 95% confidence intervals (CI), using random-effects or fixed-effects models based on heterogeneity. A total of 7441 patients from 9 phase III trials and 8 phase II trials were selected. The RR of all grade and high-grade VTEs for the TKI vs. no TKI arms was 1.10 (95% CI 0.73-1.66, p=0.64) and 0.85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found.

KW - Approved

KW - Meta-analysis

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor receptor

KW - Venous thromboembolic events

UR - http://www.scopus.com/inward/record.url?scp=84878602173&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2012.12.006

DO - 10.1016/j.critrevonc.2012.12.006

M3 - Review article

C2 - 23317774

AN - SCOPUS:84878602173

SN - 1040-8428

VL - 87

SP - 80

EP - 89

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 1

ER -

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this